Stryker Corporation · NYSE:SYK
Stryker — Merger or Acquisition (January 2025)
9 slides from Stryker's merger presentation, Jan 6, 2025
Slide 1: Stryker acquisition of Inari Medical
stryker Stryker acquisition of January 6, 2025
Slide 2: Forward-looking statements
This presentation contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such stateme
Slide 3: Tender offer notice and additional information
The tender offer for the outstanding shares of common stock of Inari referenced in this communication has not yet commenced. This communication is for informational purposes only, is not a recommendation and is neither an offer to purchase nor a solicitation of an offer to sell shares of common stoc
Slide 4: Stryker has entered into a definitive agreement to acquire Inari Medical
Stryker has entered into a definitive agreement to acquire Inari Medical, Inc. in a transaction that values the equity of the company at approximately $4.9 billion Inari’s segment-leading, high-growth and innovative peripheral vascular portfolio is highly complementary to our Neurovascular business
Slide 5: Inari overview and transaction rationale
• Founded in 2011, Inari’s portfolio includes a variety of products, including minimally invasive, novel, catheter-based mechanical thrombectomy systems to treat certain vascular diseases • Headquartered in Irvine, CA with approximately 1,400 employees • Products sold in 30+ countries, with 150,000+
Slide 6: Disease origins
Disease origins • Patients are at particularly high risk for VTE during or Blood stasis, vein injury Clot grows, becoming a Clot breaks and travels just after surgery, or hypercoagulability thrombus in a deep vein, through the bloodstream, hospitalization, cancer leads to blood clotting also known a
Slide 7: High revenue growth and underpenetrated segments
High revenue growth ($ millions) Well-positioned to serve underpenetrated segments $6031 ClotTriever® and FlowTriever® systems $494 • Minimally invasive, mechanical thrombectomy solutions designed to treat DVT and PE $383 • Clots are removed via procedures that are single-session and have establishe
Slide 8: Comprehensive interventional endovascular portfolio
• Leader in interventional • Leader in interventional neurovascular procedures peripheral vascular with innovative procedures with a proven technologies Comprehensive interventional history of innovation • Global reach and world- endovascular portfolio positioned • Strong commercial class commercial
Slide 9: Sources
• “Products sold in 30+countries, with 150,000+patients treated for venous thromboembolism (VTE)” – Sources: Inari Medical Investor Update – October 2024: https://ir.inarimedical.com/static-files/80a131bc-e63f-45a1-8dea-363d34437670; LinkedIn: https://www.linkedin.com/posts/inari-medical_inarimedica